Clinical trials: HCM
Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome
Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), Long QT Syndrome (LQTS)
- Trial name
- HiRO (NCT04189822)
- Where
- Canada
- Volunteers
- 10,000 people
- Sponsor
- University of British Columbia
Myocardial Infarction (MI), Hypertrophic Cardiomyopathy (HCM)
The Application of T1 Mapping in Real-World
The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions.
- Conditions
- Myocardial Infarction (MI), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmogenic Cardiomyopathy
- Trial name
- NCT07354646
- Testing
- Magnetic Resonance Imaging with Contrast
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging.
- Trial name
- oHCM (NCT07150299)
- Testing
- Mavacamten in clinical routine use
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Septal Hypertrophy, Obstructive Hypertrophic Cardiomyopathy
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
In some patients, septal hypertrophy extends more distally, from the subaortic portion of the septum to the midventricular portion.
- Trial name
- NCT05726799
- Testing
- Cryo myectomy, Myectomy
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Michele De Bonis
HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction
Reverse Remodeling After PTSMA in Severe But Asymptomatic LVOT Obstruction
Patients with HOCM and severe LVOT obstruction can remain asymptomatic while significant cellular and structural changes of the heart (adverse remodeling) may occur preceding heart failure and rhythm disorders.
- Conditions
- HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction, Remodeling, Ventricular
- Trial name
- RASTA (NCT04230551)
- Testing
- PTSMA
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- St. Antonius Hospital
Hypertrophic Cardiomyopathy
3D Non-invasive Myocardial Electrical Propagation Mapping as a New Tool to Predict Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is very common. The thickened heart muscle can disrupt the normal functioning of the heart's electrical system, resulting in fast or irregular heartbeats.
- Trial name
- 3D-CMH (NCT03550573)
- Testing
- CardioInsight™ Noninvasive 3D Mapping System
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Hypertrophic Obstructive Cardiomyopathy
First-in-Man Early Feasibility Study for Transcatheter HOCM Septal Ablation
Transcatheter Intra-septal RF ablation system (TIRA catheter with its supplemental devices) to treat hypertrophic obstructive cardiomyopathy.
- Trial name
- NCT04770142
- Testing
- TIRA catheter
- Where
- 9 sites in South Korea
- Volunteers
- 5 people
- Sponsor
- Tau-MEDICAL Co., Ltd.
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, Cardiomyopathies
- Trial name
- HiRO-HCM (NCT05100420)
- Where
- 17 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- Montreal Heart Institute
Hypertrophic Cardiomyopathy (HCM)
Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart condition, where the heart muscles can thicken to the point of obstructing blood flow out of the heart.
- Trial name
- MERIT HCM (NCT07332767)
- Volunteers
- 20 people
- Sponsor
- University of Manchester
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy
UTSW HP [13-C] Pyruvate Injection in HCM
The study objective is to identify the earliest changes in energy substrate metabolism in patients with cardiomyopathies (CMP). To achieve this objective, we plan first to test the hypothesis that patients with CMP present focal…
- Conditions
- Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis
- Trial name
- HPHCM (NCT03057002)
- Testing
- Hyperpolarized 13C-Pyruvate
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Obstructive Hypertrophic Cardiomyopathy
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
- Trial name
- NCT07021976
- Testing
- HRS-1893 Tablets
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hypertrophic Cardiomyopathy
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
Several studies have shown that specialized pacemaking devices (DDD pacing) can improve the symptoms associated with hypertrophic cardiomyopathy (HCM) in adults.
- Trial name
- NCT00001396
- Testing
- Paragon Pacemaker
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
- Trial name
- NCT00001878
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiomyopathy is a disease of the heart muscle. It is rare, but it can be serious. Cardiomyopathy in children can result in death, disability, heart transplantation or serious heart rhythm disorders.
- Trial name
- NCT01873976
- Where
- 13 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- Wayne State University
Hypertrophic Obstructive Cardiomyopathy (HOCM)
CArdiac Desynchronization In Obstructive HCM, CARDIO-HCM
The purpose of this study is to evaluate the benefit of the optimal pacing configuration, including the possibility of biventricular or left ventricular pacing, in hypertrophic obstructive cardiomyopathy patients.
- Trial name
- CARDIO-HCM (NCT01332162)
- Testing
- Biventricular pacing, No Pacing
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Clinic of Barcelona
1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy, 2- Obstructive Hypertrophic Cardiomyopathy
Neurohormonal Parameters in Hypertrophic Cardiomyopathies
The primary purpose of this study is to demonstrate that changes in plasma levels of circulating neurohormones (mainly BNP and NT-proBNP), measured at rest and post-exercise correlate with exercise functional limitation (assessed…
- Conditions
- 1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy, 2- Obstructive Hypertrophic Cardiomyopathy, 3- Non Obstructive Hypertrophic Cardiomyopathy
- Trial name
- REEF-CMH (NCT01729702)
- Testing
- blood sample collection
- Where
- France
- Volunteers
- 131 people
- Sponsor
- French Cardiology Society
Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Symptom Release by BX1514M
Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease characterized by an asymmetric hypertrophic. In two third of patients, an obstruction to blood ejection is observed within the left ventricle which is…
- Trial name
- Light-CARMIDO (NCT02590809)
- Testing
- Treatment BX1514M, Walk distance test, Exercise echocardiography
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
Hypertrophic Cardiomyopathy
Trimetazidine Therapy in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a common inherited heart condition that causes breathlessness, chest pain and fatigue. There are few treatments available.
- Trial name
- NCT01696370
- Testing
- Trimetazidine
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University College, London
Hypertrophic Cardiomyopathy
Echocardiography-guided Percutaneous Septal Radiofrequency Ablation for Obstructive HCM After Alcohol Septal Ablation
After alcohol ablation, some HOCM patients have serious clinical symptoms and adverse complications, and need to undergo invasive surgery again when adequate drug therapy is not effective or cannot tolerate the side effects of…
- Trial name
- HCM (NCT06496633)
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xijing Hospital
Healthy, Hypertrophic Cardiomyopathy
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
- Conditions
- Healthy, Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
- Trial name
- NCT00001632
- Where
- United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)